Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05201417
Other study ID # UJM_UB_01
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date September 15, 2019
Est. completion date June 8, 2020

Study information

Verified date January 2022
Source Support and Education Technic Centre
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A quasi-experimental and comparative study will be conducted in two different geographical areas (Europe-France and Africa-Cameroon) on a period of 18 months. All eligible adults aged 50 years and older presenting to one of the investigative centers (for HIV care) will be included in the study. The patients will be randomized in two parallel groups according to the 1:1 ratio, namely a control group A where patients continue the usual HIV management, and an intervention group B where in addition to the usual HIV management, patients will benefit from an adapted physical activity (APA) program for three months. An evaluation of heart rate variability, response to current treatment, gut microbiota profile and quality of life will be performed at the end of the APA session. Comparison between control group A and intervention group B will be performed. The acceptability of this program will also be evaluated.


Description:

Purpose: The objective of our study was to measure the effect of a physical activity training program on heart rate variability (ANS) in PLWHIV in 2 different geographical areas (Europe-France and Africa-Cameroon). Investigators also propose to measure the impact of this program on inflammation markers such as IL-6, ultra-sensitive CRP and Cystatin C, on the quality of the microbiota of PLHIV and TMAO. participants and methods: Investigators will conduct a comparative study that involved subjects aged from 50 years and above, recruited from June 2019 to June 2020 at Mvog Ada district hospital This study will be conducted in 3 phases: - Phase 1: All eligible adults aged 50 years and older presenting to one of the investigative centers (for HIV care) will be included in the study. The standardized program of adapted physical activity is proposed on the basis of the specifications of adapted physical activities. The participants will be randomized in two parallel groups according to the 1:1 ratio, namely a control group A where participants continue their usual HIV management, and an intervention group B where in addition to the usual HIV management, participants will benefit from an adapted physical activity program. Information regarding heart rate variability and ANS dysfunction will be collected via an overnight recording with the NeuroCoach device (recording box). A questionnaire (to determine the level of physical activity, on compliance with current treatment and quality of life) will be administered. - Second phase: intervention phase The adapted physical activity program will be offered systematically to all participants in group B. The standardized program of adapted physical activity is proposed on the basis of the specifications of adapted physical activities. An evaluation of heart rate variability, response to current treatment, gut microbiota profile and quality of life will be performed at the end of the APA sessions. Comparison between control group A and intervention group B will be performed. - The third phase: post-program follow-up: six months At the end of the intervention phase, post-program follow-up will be done through interviews until six months after the end of the intervention. All the participants included will be able to benefit, at their request, a counseling session related to the adapted physical activity program, in order to reinforce integration of physical activity into their day to day routine.


Recruitment information / eligibility

Status Completed
Enrollment 112
Est. completion date June 8, 2020
Est. primary completion date June 6, 2020
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 50 Years to 77 Years
Eligibility Inclusion Criteria: - People aged 50 to 77 years ; - People living with HIV in one of the 2 study'countries; - People without medical contraindications to participate in moderate physical activity - People who has received information about the study and its rights to its data. Exclusion Criteria: - Patient under guardianship or curatorship; - Having a contraindication to physical activity (medical certificate); - Infected with HIV-2 alone; - Hospitalized, in end of life care; - Morbidly obese (BMI > 40).

Study Design


Related Conditions & MeSH terms


Intervention

Other:
adapted physical activity
The adapted physical activity will be administered remotely through the whatsApp or YouTube application. Two sessions will be done per week: Wednesday and Sunday. Walking seems to be appropriate for all participants We will account for 24 APA sessions. We will leverage the Step Tracker phone app and pedometer to get the number of steps done, number of calories spent, Workout duration and distance walked per participant per APA session; this data will be collected weekly (after every two sessions)

Locations

Country Name City State
Cameroon Mvog Ada district Hospital Yaoundé Centre
France CHU Saint étienne Saint-Étienne
France CHU Saint-Etienne Saint-Étienne

Sponsors (1)

Lead Sponsor Collaborator
Support and Education Technic Centre

Countries where clinical trial is conducted

Cameroon,  France, 

Outcome

Type Measure Description Time frame Safety issue
Other Smoking answering "yes" to the question do you smoke? At inclusion
Other Alcoholism answering "yes" to the question do you consume alcohol? At inclusion
Other Body mass index 3 modalities was defined according to BMI. Underweight (BMI < 18.5 Kg/m2), normal weight (18 = BMI < 25 Kg/m²), overweight (25 = BMI < 30 Kg/m²), obesity (BMI = 30 Kg/m²). At inclusion
Other Systolic Blood Pressure (mmHg) Systolic blood pressure = 140 mmHg or taking a hypotensive treatment. At inclusion
Other Diastolic Blood Pressure (mmHg) diastolic = 90 mmHg or taking a hypotensive treatment. At inclusion
Primary heart failure evaluated by summing the participant's factors contributing to heart rate variability. The Neurocoach records a 24-hour electrocardiogram (ECG). From this 24-hour recording, 3 types of variable are given, cardiac arrhythmias, Autonomic nervous system (ANS) activity, Sleep apnea parameters. the punctual analysis of the neurocoach recording makes it possible to highlight atrial fibrillation (AF) and sleep apnea, factors known to promote the risk of a cardiovascular accident At inclusion and after 24 weeks
Primary cardiovascular risks factors evaluated by summing the participant's cardiovascular risk factors. The cardiovascular risk factors assess were metabolic disorders(Total cholesterol, HDL cholesterol, Triglyceride), smoking, physical inactivity, alcohol consumption (defined by an AUDIT score = 8), overweight or obesity, hypertension, and diabetes. The cardiovascular risk was considered high if the subject had a combination of at least 3 cardiovascular risk factors. At inclusion and after 24 weeks
Secondary total cholesterol ( mg/l) <190mg/dl = normal and >190 mg/dl = high At inclusion , up to 12 weeks and after 24 weeks
Secondary HDL cholesterol ( mg/dl) Men (> 55 mg /dl = normal; 35 - 55 mg/dl = intermidiate; < 35 mg/dl = low ) women (> 65 mg/dl = normal; 45 - 65 mg/dl = intermidiate, < 45 mg/dl = low) At inclusion , up to 12 weeks and after 24 weeks
Secondary Triglyceride (mg/dl) Normal: <150 mg/dl, slightly elevated: 150-200mg/dl, high 200 - 500 mg/dl and very high = 500 mg/dl At inclusion , up to 12 weeks and after 24 weeks
Secondary atrial fibrillation-type heart rhythm disturbances Atrial fibrillation occurs when action potentials fire very rapidly within the pulmonary veins or atrium in a chaotic manner. Because the atrial rate is so fast, and the action potentials produced are of such low amplitude, P waves will not be seen on the ECG in patients with atrial fibrillation.
the Neurocoach is worn by the participant overnight, allowing the investigator to analyze their nightly ECG recording.
At inclusion and after 24 weeks
Secondary an indirect approach to the presence of sleep apnea Heart rate allows to count sleep apnea events. Neurocoach records a 24-hour electrocardiogram (ECG). From this 24-hour recording a sleep apnea are notice throw heart rate decreases due to the stretching of mechanical receptors of the lungs. Once the ventilation resumes, heart rate increases due to the hypoxia stimuli accumulated during the apnea. These swings in heart rate allow to quantify sleep apnea.
AHI (Apnea/Hypopnea Index): number of breaths stopped (apneas) or number of shallow breaths (hypopneas) per hour of sleep.
From 5 to 15 ...... Mild Sleep Apnoea Syndrome
15 to 30 .... Moderate Sleep Apnoea Syndrome
More than 30 ..... Severe Sleep Apnoea Syndrome.
At inclusion and after 24 weeks
Secondary disturbances in the activity of the autonomic nervous system Neurocoach records a 24-hour electrocardiogram (ECG). From this 24-hour recording the variations of the RR intervals which are dependent on the innervation by the Autonomic Nervous System (ANS) which modify the RR intervals on short terms, from one interval to the other, as well as on longer terms.From the analysis of the variations of this intervals, one can deduce the activity of the ANS
The parasympathetic and sympathetic variables are better separated using Fourier Transform:
High Frequency (HF 0,15 et 0,4 Hz.) gives the parasympathetic activity
Low frequency (LF 0,04 et 0,15 Hz) gives the sympathetic activity
The LF/HF ratio gives the equilibrium between both activities Ratio < 2 .......... balanced sympathetic-vagal balance
2 < Ratio < 4 .... slightly unbalanced sympathetic-vagal balance
4 < Ratio < 6 .... unbalanced sympathetic-vaginal balance
6 < Ratio .......... strongly unbalanced sympathetic-vagal balance
At inclusion and after 24 weeks
Secondary inflammatry marker(Il-6) nomal range 5-15 pg/ml At inclusion , up to 12 weeks and after 24 weeks
Secondary Cystatin C (mg/l) Normal : 0.48 - 0.82 (woman < 60 years) 0.54 - 0.94 (man < 60 years) and 0.63 - 1.03 (= 60 years) At inclusion , up to 12 weeks and after 24 weeks
Secondary ultra sensitive CRP. Low risk of developing cardiovascular disease (<1.0 mg / l); Average risk of developing cardiovascular disease (1.0 to 3.0 mg / L); High risk of developing cardiovascular disease (3.0-10.0 mg / L); Other cause of inflammation (> 10.0 mg / L) At inclusion , up to 12 weeks and after 24 weeks
Secondary gut microbiota Quantification of the most important probiotics in the gut microbiota (Faecalibacterium and Eubacterium) by RT-q PCR At inclusion and after 24 weeks
Secondary adapted physical activity The adapted physical activity will be administered remotely through the whatsApp or YouTube application. Two sessions will be done per week: Wednesday and Sunday. Walking seems to be appropriate for all participants. We will account for 24 APA sessions. We will leverage the Step Tracker phone application to get the number of steps doneand Workout duration (minute) per APA session; this data will be collected weekly 12 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT05196659 - Collaborative Quality Improvement (C-QIP) Study N/A
Recruiting NCT05650307 - CV Imaging of Metabolic Interventions
Recruiting NCT05654272 - Development of CIRC Technologies
Active, not recruiting NCT05896904 - Clinical Comparison of Patients With Transthyretin Cardiac Amyloidosis and Patients With Heart Failure With Reduced Ejection Fraction N/A
Completed NCT05077293 - Building Electronic Tools To Enhance and Reinforce Cardiovascular Recommendations - Heart Failure
Recruiting NCT05631275 - The Role of Bioimpedance Analysis in Patients With Chronic Heart Failure and Systolic Ventricular Dysfunction
Enrolling by invitation NCT05564572 - Randomized Implementation of Routine Patient-Reported Health Status Assessment Among Heart Failure Patients in Stanford Cardiology N/A
Enrolling by invitation NCT05009706 - Self-care in Older Frail Persons With Heart Failure Intervention N/A
Recruiting NCT04177199 - What is the Workload Burden Associated With Using the Triage HF+ Care Pathway?
Terminated NCT03615469 - Building Strength Through Rehabilitation for Heart Failure Patients (BISTRO-STUDY) N/A
Recruiting NCT06340048 - Epicardial Injection of hiPSC-CMs to Treat Severe Chronic Ischemic Heart Failure Phase 1/Phase 2
Recruiting NCT05679713 - Next-generation, Integrative, and Personalized Risk Assessment to Prevent Recurrent Heart Failure Events: the ORACLE Study
Completed NCT04254328 - The Effectiveness of Nintendo Wii Fit and Inspiratory Muscle Training in Older Patients With Heart Failure N/A
Completed NCT03549169 - Decision Making for the Management the Symptoms in Adults of Heart Failure N/A
Recruiting NCT05572814 - Transform: Teaching, Technology, and Teams N/A
Enrolling by invitation NCT05538611 - Effect Evaluation of Chain Quality Control Management on Patients With Heart Failure
Recruiting NCT04262830 - Cancer Therapy Effects on the Heart
Completed NCT06026683 - Conduction System Stimulation to Avoid Left Ventricle Dysfunction N/A
Withdrawn NCT03091998 - Subcu Administration of CD-NP in Heart Failure Patients With Left Ventricular Assist Device Support Phase 1
Recruiting NCT05564689 - Absolute Coronary Flow in Patients With Heart Failure With Reduced Ejection Fraction and Left Bundle Branch Block With Cardiac Resynchronization Therapy